M
Margaret A. Johnson
Researcher at University of Alabama at Birmingham
Publications - 322
Citations - 14219
Margaret A. Johnson is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Viral load & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 61, co-authored 311 publications receiving 13635 citations. Previous affiliations of Margaret A. Johnson include University of Alberta & Simon Fraser University.
Papers
More filters
Journal ArticleDOI
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
Brian Gazzard,Jane Anderson,Abdel Babiker,Marta Boffito,Gary Brook,Gary Brough,Duncan Churchill,Ben Cromarty,Satyajit Das,Martin Fisher,Andrew L. Freedman,Anna Maria Geretti,Margaret A. Johnson,Saye Khoo,Clifford Leen,Devaki Nair,Barry Peters,Andrew N. Phillips,Deenan Pillay,Anton Pozniak,John P. Walsh,Ed Wilkins,Ian S. Williams,Matthew Williams,M Youle +24 more
TL;DR: The 2008 BHIVA Guidelines have been updated to incorporate all the new relevant information since the last iteration and all the peer-reviewed publications and important, potentially treatment-changing abstracts from the last 2 years have been reviewed.
Journal ArticleDOI
Validation of housekeeping genes for normalizing RNA expression in real-time PCR
Keertan Dheda,Jim F. Huggett,Stephen A. Bustin,Margaret A. Johnson,Graham A. W. Rook,Alimuddin Zumla +5 more
TL;DR: Real-time reverse transcription PCR is used to assess the levels of 13 housekeeping genes expressed in peripheral blood mononuclear cell culture and whole blood from healthy individuals and those with tuberculosis and shows that RNA specifying human acidic ribosomal protein was the most suitable housekeeping gene for normalizing mRNA levels in human pulmonary tuberculosis.
Journal ArticleDOI
Dysferlin is a Plasma Membrane Protein and is Expressed Early in Human Development
Louise V.B. Anderson,Keith Davison,Jennifer A. Moss,Carol Young,Michael Cullen,John P. Walsh,Margaret A. Johnson,Rumaisa Bashir,S. Britton,Sharon Keers,Zohar Argov,Ibrahim Mahjneh,Françoise Fougerousse,Jacques S. Beckmann,Kate Bushby +14 more
TL;DR: Analysis of human fetal tissue showed that dysferlin was expressed at the earliest stages of development examined, at Carnegie stage 15 or 16 (embryonic age 5-6 weeks).
Journal ArticleDOI
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Schlomo Staszewski,Philip Keiser,Julio S. G. Montaner,François Raffi,Joe Gathe,Vitor Brotas,Charles B. Hicks,Scott M. Hammer,David A. Cooper,Margaret A. Johnson,Stephanie M. Tortell,Amy Cutrell,D. Thorborn,Robin Isaacs,Seth Hetherington,Helen C. Steel,William Spreen +16 more
TL;DR: In this study of antiretroviral-naive HIV-infected adults, the triple nucleoside regimen of abacavir-lamivudine-zidovudine -zidvudine was equivalent to the regimen of indinavir- LamivUDine-ZidovUDine in achieving a plasma HIV RNA level of less than 400 copies/mL at 48 weeks.
Journal ArticleDOI
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Graeme Moyle,Caroline A. Sabin,J. D. Cartledge,Margaret A. Johnson,Edmund Wilkins,Duncan Churchill,P Hay,Ade Fakoya,Maurice Murphy,G. Scullard,Clifford Leen,Geraldine Reilly +11 more
TL;DR: Switching from a thymidine nucleoside analogue to either tenofovir disoproxil fumarate (DF) or abacavir leads to significant improvement in limb fat mass over 48 weeks, and ten ofovir DF may have modest advantages over abacvir for changes in lipids.